Summary
Purpose: This phase II study explored the efficacy and tolerability of pegylated liposomal doxorubicin (PLD) given on a 2 week schedule in patients with advanced malignant melanoma previously untreated by chemotherapy.
Patients and methods: Patients with inoperable, advanced melanoma were treated with Pegylated liposomal doxorubicin (Caelyx®) at a dose of 20 mg/m2 every 2 weeks. Treatment cycles were repeated every 4 weeks for a maximum of 6 cycles. Patients with responding or stable disease at the end of study treatment, as assessed by using NCI CTG criteria, could continue PLD off-study.
Results: PLD administered as a 2 weekly IV infusion was well tolerated with mild infusion reactions usually associated with the first infusion. Myelosuppression was mild, as was nausea and vomiting. Palmar plantar erythrodysesthesia was also uncommon using this schedule. There were no objective responses seen in the 14 evaluable patients. Enrollment was stopped as per protocol, due to lack of activity.
Conclusion: PLD was well tolerated using a 2 week schedule but failed to show any activity in chemotherapy naive patients with advanced malignant melanoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balch CM, Houghton AN, Sober AJ, Soong S (1998) Cutaneous Melanoma, 3rd edn. Quality Medical Publishing, St. Louis MO
Canadian Cancer Statistics (2004) National Cancer Institute, Toronto, Canada
DeVita VT, Hellman S, Rosenberg SA (eds) (2001) Cancer principals and practice oncology, 6th edn. Lippincott, Philadelphia, PA
McClay EF, McClay MET (1996) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 23:744–753
Chapman PB, Einhorn LH, Meyers ML et al (1999) A phase III multicenter trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745–2751
Richards JM, Gale D, Mehta N et al (1999) Combination of chemotherapy with interleukin-2 and interferon alpha in patients with metastatic melanoma. J Clin Oncol 17:651–657
Legha SS, Ring S, Eton O et al (1997) Development and results of biochemotherapy in metastatic melanoma. The University of Texas MD Anderson Experience. Cancer J Sci Am 3:S9–S15
Khayat D, Borel C, Tourani J et al (1993) Sequential chemo immunotherapy with cisplatin, interleukin-2 and interferon alfa-2 for metastatic melanoma. J Clin Oncol 11:2173–2180
Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968–975
Eaton O, Legha S, Bedikian A et al (2002) Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (INF) versus CVD in patients with metastatic melanoma. J Clin Oncol 20:2045–2052
Sieper WJ, Mastrangelo MJ, Bellet RE (1975) A phase II study of Adriamycin in patients with metastatic melanoma. Cancer Chemotherapy Rep 59:1181–1182
Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A (1998) Treatment of advanced breast cancer with stereotactically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Cli Oncol 16(2):811–812
Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS (1999) Phase II trial of doxil for patients with melanoma refractory to frontline therapy. Oncol Rep 6:1097–1099
Vorobiof DA et al (2003) Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Res 13(2):201–203
Acknowledgments
We thank Schering Canada Inc for providing the pegylated liposomal doxorubicin (CaelyxTM) used in this study.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smylie, M.G., Wong, R., Mihalcioiu, C. et al. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest New Drugs 25, 155–159 (2007). https://doi.org/10.1007/s10637-006-9002-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-006-9002-y